New gene-editing tech repurposes bacterial retrons to correct large stretches of DNA

Some genetic disorders—such as cystic fibrosis, hemophilia and Tay Sachs disease—involve many mutations in a person's genome, ...
Nasdaq

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder ...

NEW YORK& TOKYO---- Pfizer Inc. and Astellas Pharma Inc. today announced that on January 26 the European Medicines Agency validated for review a Type II variation application for PADCEV ® with ...
Healio

FDA approves lurbinectedin, atezolizumab combination for small cell lung cancer

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...
Pharm Exec

FDA Approves Zepzelca in Combination with Atezolizumab for Extensive-Stage Small Cell Lung Cancer Therapy

The FDA approved Zepzelca and Atezolizumab for ES-SCLC maintenance therapy after successful first-line induction therapy. The Phase III IMforte trial showed a 46% reduction in disease progression risk ...
Healio

GOLD-STANDARD trial will test novel combination therapy for diabetic kidney disease

Please provide your email address to receive an email when new articles are posted on . A four-drug combination administered early may be a better strategy for treating diabetic kidney disease than ...
Nasdaq

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder ...

TOKYO and NEW YORK, Jan. 26, 2024/ PRNewswire/-- Astellas Pharma Inc. and Pfizer Inc. today announced that on Jan. 26, 2024 the European Medicines Agency validated for review a Type II variation ...